Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - What's Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $15.74, but opened at $16.59. Tyra Biosciences shares last traded at $16.18, with a volume of 15,912 shares trading hands.

Analyst Ratings Changes

A number of research firms recently issued reports on TYRA. HC Wainwright decreased their price objective on Tyra Biosciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday. Wedbush reaffirmed an "outperform" rating and issued a $28.00 price target on shares of Tyra Biosciences in a report on Friday, October 25th. Oppenheimer upped their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a report on Thursday, September 19th. Piper Sandler initiated coverage on Tyra Biosciences in a report on Thursday, August 15th. They set an "overweight" rating and a $33.00 target price for the company. Finally, Bank of America upgraded Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has a consensus rating of "Buy" and an average price target of $31.00.

Tyra Biosciences Stock Up 3.8 %

The company's fifty day simple moving average is $21.51 and its 200 day simple moving average is $19.98. The firm has a market capitalization of $826.80 million, a PE ratio of -10.15 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.56 EPS for the current year.

Insider Buying and Selling

In other Tyra Biosciences news, CEO Todd Harris sold 10,092 shares of Tyra Biosciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the completion of the transaction, the chief executive officer now directly owns 1,479,528 shares of the company's stock, valued at approximately $35,701,010.64. The trade was a 0.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alan Fuhrman bought 9,500 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the purchase, the chief financial officer now owns 12,849 shares of the company's stock, valued at approximately $205,584. This represents a 283.67 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 101,050 shares of company stock worth $2,235,492 in the last 90 days. Insiders own 15.40% of the company's stock.

Institutional Investors Weigh In On Tyra Biosciences

Several large investors have recently bought and sold shares of TYRA. Walleye Capital LLC lifted its holdings in Tyra Biosciences by 306.5% in the third quarter. Walleye Capital LLC now owns 126,597 shares of the company's stock valued at $2,976,000 after acquiring an additional 95,451 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Tyra Biosciences in the 3rd quarter worth $593,000. Ally Bridge Group NY LLC raised its stake in shares of Tyra Biosciences by 2.0% in the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company's stock worth $6,349,000 after buying an additional 5,415 shares during the period. FMR LLC raised its stake in Tyra Biosciences by 0.8% during the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company's stock worth $79,296,000 after acquiring an additional 26,187 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences during the 3rd quarter valued at $333,000. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.